T7572
Thrombin aus Humanplasma
400-1000 NIH units/mg protein
Synonym(e):
Faktor IIa
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empfohlene Produkte
Form
lyophilized powder
Qualitätsniveau
Spezifische Aktivität
400-1000 NIH units/mg protein
Verunreinigungen
HIV, hepatitis B and hepatitis C, tested negative
UniProt-Hinterlegungsnummer
Lagertemp.
−20°C
Angaben zum Gen
human ... F2(2147)
Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich
Allgemeine Beschreibung
Lyophilized powder containing sucrose, sodium chloride and Tris.
Thrombin is the final coagulation protease in regard to hemostasis, promoting both procoagulant and anticoagulant effects.
Anwendung
Thrombin is used for site specific cleavage of recombinant fusion proteins containing an accessible thrombin recognition site for removal of affinity tags. Thrombin has been used in a study to assess an innovative flow cytometric approach for small-size platelet microparticles.
Biochem./physiol. Wirkung
Serinprotease, die selektiv Arg-Gly-Bindungen in Fibrinogen spaltet, um Fibrin und Fibrinopeptide A und B zu bilden.
Einheitendefinition
Activity is expressed in NIH units obtained by direct comparison to a NIH Thrombin Reference Standard
Hinweis zur Analyse
The NIH assay procedure uses 0.2 ml diluted plasma (1:1 with saline) as a substrate and 0.1ml of thrombin sample (stabilized in a 1% buffered albumin solution) based on a modification of the method of Biggs. Only clotting times in the range of 15-25 seconds are used for determining thrombin concentrations.
Sonstige Hinweise
Für weitere Informationen siehe thrombin at www.sigma-aldrich.com/enzymeexplorer.
Haftungsausschluss
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Kunden haben sich ebenfalls angesehen
An innovative flow cytometric approach for small-size platelet microparticles: influence of calcium.
Silvia Montoro-García et al.
Thrombosis and haemostasis, 108(2), 373-383 (2012-06-29)
Microparticles (MPs) are small submicron membrane-derived vesicles shed from a variety of cells and they have been implicated in different disorders. Accordingly, understanding of physiological characteristics of MPs and improvement of methods of their quantification are important for further advance
At the cutting edge: conformational PARtiality.
T Madhusudhan et al.
Journal of thrombosis and haemostasis : JTH, 10(8), 1672-1674 (2012-06-30)
Jawed Fareed et al.
Annual review of pharmacology and toxicology, 52, 79-99 (2011-08-09)
Since the discovery of heparin nearly a century ago, there have been large gaps in the development of anticoagulants. The discovery of warfarin was the first step toward using oral anticoagulants, but warfarin use has been associated with its own
Herbert Nar
Trends in pharmacological sciences, 33(5), 279-288 (2012-04-17)
The quest for novel medications to treat thromboembolic disorders such as venous thrombosis, pulmonary embolism and stroke received a boost when the 3D structures of two major players in the blood coagulation cascade were determined in 1989 and 1993. Structure-guided
Walter-Michael Halbmayer et al.
Clinical chemistry and laboratory medicine, 50(9), 1601-1605 (2012-10-27)
Dabigatran etexilate is a new oral anticoagulant for the therapy and prophylaxis of venous thromboembolism and stroke prevention in patients with atrial fibrillation. To investigate the extent of interactions of this new anticoagulant with frequently used coagulation assays, we completed
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.